Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population

References

• Centers for Disease Control and Prevention. Atrial Fibrillation. 2020 [cited 2020 Sep 9]. Available from: https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
   Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313–320.
   PubMed Web of Science ®Google Scholar
• Lim GB. Atrial fibrillation. Risk of systemic emboli in AF. Nat Rev Cardiol. 2015;12:561.
   PubMedGoogle Scholar
• Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther. 2010;8:1711–1721.
   PubMedGoogle Scholar
• Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1:139–152.
   PubMedGoogle Scholar
• Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. Jama. 2004;292:2471–2477.
   PubMed Web of Science ®Google Scholar
• Nalliah CJ, Sanders P, Kottkamp H, et al. The role of obesity in atrial fibrillation. Eur Heart J. 2016;37:1565–1572.
   PubMed Web of Science ®Google Scholar
• Pandey A, Gersh BJ, McGuire DK, et al. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC Clin Electrophysiol. 2016;2:355–363.
   PubMedGoogle Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
   PubMed Web of Science ®Google Scholar
• Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501–1508.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Adult obesity facts. 2020 [cited 2020 Sep 9]. Available from: https://www.cdc.gov/obesity/data/adult.html
   Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
   PubMed Web of Science ®Google Scholar
• Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127:e15–e16.
   Web of Science ®Google Scholar
• American College of Cardiology F, American Heart A, European Society of C, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:1916–1926.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. ELIQUIS® (apixaban) – prescribing information. 2019 [cited 2020 Sep 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202155s024lbl.pdf
   Google Scholar
• United States Food and Drug Administration. PRADAXA® (dabigatran etexilate) – prescribing information. 2020 [cited 2020 Sep 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022512s039lbl.pdf
   Google Scholar
• United States Food and Drug Administration. XARELTO® (rivaroxaban) – Prescribing Information. 2021 [cited 2021 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022406s036,202439s036lbl.pdf
   Google Scholar
• Saraiva JFK. Stroke prevention with oral anticoagulants: summary of the evidence and efficacy measures as an aid to treatment choices. Cardiol Ther. 2018;7:15–24.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lip GY. Non-vitamin K oral anticoagulants in atrial fibrillation: where are we now? Trends Cardiovasc Med. 2015;25:315–336.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50:e1–e88.
   PubMed Web of Science ®Google Scholar
• Compendium EM. SPC. Warfarin 0.5 mg tablets. 2017 [cited 2019 Nov 22]. Available from: https://www.medicines.org.uk/emc/medicine/27651
   Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.
   PubMed Web of Science ®Google Scholar
• Domienik-Karlowicz J, Pruszczyk P. The use of anticoagulants in morbidly obese patients. Cardiol J. 2016;23:12–16.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218–244.
   PubMed Web of Science ®Google Scholar
• Willmann S, Zhang L, Frede M, et al. Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations. CPT Pharmacometrics Syst Pharmacol. 2018;7:309–320.
   PubMedGoogle Scholar
• Barsam SJ, Patel JP, Roberts LN, et al. The impact of body weight on rivaroxaban pharmacokinetics. Res Pract Thromb Haemost. 2017;1:180–187.
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–1313.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
   PubMed Web of Science ®Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415.
   PubMed Web of Science ®Google Scholar
• Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510.
   PubMed Web of Science ®Google Scholar
• Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Feuring M, et al. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res. 2012;130:818–820.
   PubMed Web of Science ®Google Scholar
• Pineo G, Gallus A, Raskob G, et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013;11:444–451.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost. 2011;105:444–453.
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–328.
   PubMed Web of Science ®Google Scholar
• Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908–916.
   PubMed Web of Science ®Google Scholar
• Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation. European Journal of Clinical Pharmacology. 2014;70:1339–1351.
   PubMed Web of Science ®Google Scholar
• Mueck W, Lensing AW, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675–686.
   PubMed Web of Science ®Google Scholar
• Kido K, Ngorsuraches S. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2019;53:165–170.
   PubMed Web of Science ®Google Scholar
• Peterson ED, Ashton V, Chen YW, et al. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J. 2019;212:113–119.
   PubMed Web of Science ®Google Scholar
• Costa OS, Beyer-Westendorf J, Ashton V, et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin. 2020;36:1081–1088.
   PubMed Web of Science ®Google Scholar
• Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol. 2019;6:e359–e365.
   PubMed Web of Science ®Google Scholar
• Perales IJ, San Agustin K, DeAngelo J, et al. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann Pharmacother. 2020;54:344–350.
   PubMed Web of Science ®Google Scholar
• Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). Am J Cardiol. 2017;119:1989–1996.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther. 2015;32:216–227.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Pilon D, Raut MK, et al. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin. 2014;30:1521–1528.
   PubMed Web of Science ®Google Scholar
• Jain R, Watzker A, Luo X, et al. Validation of obesity coding among newly treated nonvalvular atrial fibrillation patients using an integrated electronic medical record and claims database. Curr Med Res Opin. 2020;36:189–197.
   PubMed Web of Science ®Google Scholar
• Schroeder KM, Gelwicks S, Naegeli AN, et al. Comparison of methods to estimate disease-related cost and healthcare resource utilization for autoimmune diseases in administrative claims databases. Clinicoecon Outcomes Res. 2019;11:713–727.
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–3679.
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228–1234.
   Web of Science ®Google Scholar
• Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther. 2015;37:554–562.
   PubMed Web of Science ®Google Scholar
• Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014;129:1407–1414.
   PubMed Web of Science ®Google Scholar
• Barnes GD, Misirliyan S, Kaatz S, et al. Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. Implement Sci. 2017;12:87.
   PubMed Web of Science ®Google Scholar
• Martin BJ, Chen G, Graham M, et al. Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies. BMC Health Serv Res. 2014;14:70.
   PubMed Web of Science ®Google Scholar
• Lloyd JT, Blackwell SA, Wei II, et al. Validity of a claims-based diagnosis of obesity among medicare beneficiaries. Eval Health Prof. 2015;38:508–517.
   PubMed Web of Science ®Google Scholar
• Ammann EM, Kalsekar I, Yoo A, et al. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data. Pharmacoepidemiol Drug Saf. 2018;27:1092–1100.
   PubMed Web of Science ®Google Scholar